Zimmer submits Monogram robot to FDA

Zimmer Biomet submitted its autonomous Monogram robot for FDA clearance, aiming for approval in 2027. The company acquired Monogram in 2025 for $177M. Clinical trials showed no safety events, with potential time savings and accuracy improvements. CEO Ivan Tornos expects FDA review may involve back-and-forth due to the technology's novelty.

Original reporting
Published Nov 20, 2026, 4:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zimmer submits Monogram robot to FDA — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

The filing introduces a new regulatory milestone that could affect Zimmer Biomet's growth outlook and valuation.

02

Market read

First‑time FDA 510(k) submission for an autonomous surgical robot, a material regulatory event for a mid‑cap medical‑device firm.

03

What to watch

Potential cost overruns in scaling the autonomous platform and surgeon adoption rates.

Relevance 7/10Novelty 8/10Timing: today

Background

Zimmer Biomet acquired Monogram Technologies in 2025 and is now seeking clearance for a fully autonomous version of the robot, differentiating it from its existing Rosa system.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Zimmer Biomet filed a 510(k) submission for its autonomous Monogram orthopedic robot, a new regulatory filing not previously reported.

Expected impact

likely modest upside as investors anticipate FDA approval timeline.

Evidence & confidence

Regulatory filings for novel medical devices often boost stock ahead of clearance, especially for a mid‑cap device maker.

Market effects

May signal increased competition in autonomous orthopedic robotics, affecting peers like Stryker (SYK).

U.S. medical‑device sector could see modest uplift.

Limited to U.S. device market; no immediate global ripple.

Counterpoint

If FDA delays or requires additional data, the stock could face downside pressure.

Key entities

  • Zimmer Biomet

    Medical device maker pursuing autonomous orthopedic robot.

  • Monogram Technologies

    Developer of the Monogram robot acquired by Zimmer Biomet.

Related articles

$ZBHMed

Why is Zimmer Biomet stock climbing today?

Zimmer Biomet (ZBH) stock rose 1.8% after Wells Fargo upgraded it to Overweight with a $123 price target, citing the upcoming Monogram robotic system launch. Stifel raised its target to $140, while BMO lowered its target to $101. The stock gained despite broader market declines, reaching an intraday high of $104.28.

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.